Real-World Evidence of Aripiprazole Tablets with Sensor: Treatment Patterns and Impacts on Psychiatric Healthcare Resource Utilization

• Main Authors: Hadzi Boskovic D (Author), Liang S (Author), Parab P (Author), Wiggins E (Author), Liberman JN (Author)
• Format: Book
• Published: Dove Medical Press, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1178-6981
• Keywords: serious mental illness; digital medicine system; digital health; clinical decision-making; Medicine (General); R5-920; Therapeutics. Pharmacology; RM1-950
• Source: ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 487-498 (2023)

Dusica Hadzi Boskovic,1 Shuting Liang,2 Purva Parab,2 Emily Wiggins,2 Joshua N Liberman2 1Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA; 2Health Analytics, LLC, Clarksville, MD, USACorrespondence: Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ, 08540, USA, Tel [phone], Email [e-mail]: Maintaining adherence to antipsychotic (AP) medication is often challenging. Aripiprazole tablets with sensor (AS) contain an ingestible event marker and communicate with wearable patches and a smartphone app to provide objective medication ingestion data. This study evaluated real-world treatment patterns of AS usage and its impact on psychiatric healthcare resource utilization (HCRU).Patients and Methods: This retrospective, observational cohort study identified individuals who initiated AS between 1/1/2019 and 6/30/2020 with 3 months baseline and 6 months of follow-up data using a commercial medical and pharmacy claims database (Clarivate). Controls were propensity score-matched (4:1) to AS initiators based on age (± 2 years), sex, diagnosis (major depressive disorder [MDD], schizophrenia, bipolar I disorder [BP-I], other), insurance, and baseline oral AP use (yes/no). Days of AP supply were evaluated using a general regression model. The frequency of psychiatric HCRU during follow-up was compared between groups using a zero-inflated regression model.Results: Most AS initiators were diagnosed with MDD (61.2%) and were women (61.2%); mean age was 37.7 years (standard deviation: 14.1). Most AS initiators (53.1%) continued treatment for > 60 days (mean days of supply = 77). After adjusting for covariates, AS initiators had 41% more days of AP supply during follow-up compared with controls (P < 0.0001) and significantly lower adjusted odds ratios (ORs) for psychiatric outpatient visits (adjusted OR = 0.80; P < 0.05), emergency department visits (adjusted OR = 0.11; P < 0.05), inpatient visits (adjusted OR = 0.42; P < 0.05), and other medical services (adjusted OR = 0.25; P < 0.05).Conclusion: Participants who implemented AS had significantly more days of AP supply and fewer psychiatric care visits. These preliminary results suggest AS usage can help build regular medication-taking habits and holds promise for reducing psychiatric HCRU. Additional studies with larger sample sizes are warranted to inform clinical practice and coverage decisions.Keywords: serious mental illness, digital medicine system, digital health, clinical decision-making